Glucagon-like peptide-1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity-a systematic review and network meta-analysis.

Shamim MA, Patil AN, Amin U, Roy T, Tiwari K, Husain N, Kumar J, Chenchula S, Rao P, Ganesh V, Varthya SB, Singh S and 8 more

Show all authors

Shukla R, Rastogi A, Gandhi AP, Satapathy P, Sah R, Padhi BK, Dwivedi P, Khunti K

Diabetes, obesity & metabolism23 Jul 2024Cited by 16 (Europe PMC)

PMID39044306DOI10.1111/dom.15777PepBankPUB-39044306

Publisher page PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

2 results from studies that gave the peptide. 2 results from people.

01HumanSystematic reviewEfficacy outcome
In the network meta-analysis in adolescents with overweight or obesity, semaglutide led to the greatest weight reduction, ahead of exenatide, liraglutide and lixisenatide.
In plain wordsIn adolescents with overweight or obesity, semaglutide gave the greatest weight loss among the GLP-1 drugs compared.
Peptide
Semaglutide
Outcome
DecreaseWeight reduction ranking in network meta-analysis
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
In the NMA, semaglutide led to the greatest weight reduction, followed by exenatide, liraglutide and lixisenatide.
1 context sentence(design, population, supporting numbers)
Summary · context
For this systematic review and network meta-analysis, we searched five databases and registries until 2 March 2024 for eligible randomized controlled trials (RCTs).
Report a problemFND-3904430605
02HumanSystematic reviewEfficacy outcome
In the network meta-analysis in adolescents with overweight or obesity, liraglutide ranked third for weight reduction, after semaglutide and exenatide and ahead of lixisenatide.
In plain wordsIn adolescents with overweight or obesity, liraglutide ranked third for weight loss among the GLP-1 drugs compared.
Peptide
Liraglutide
Outcome
DecreaseWeight reduction ranking in network meta-analysis
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
In the NMA, semaglutide led to the greatest weight reduction, followed by exenatide, liraglutide and lixisenatide.
1 context sentence(design, population, supporting numbers)
Summary · context
For this systematic review and network meta-analysis, we searched five databases and registries until 2 March 2024 for eligible randomized controlled trials (RCTs).
Report a problemFND-3904430606

Studies that did not test the peptide alone4

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adolescents with overweight or obesity, pooled GLP-1 receptor agonists (including liraglutide) reduced weight versus placebo by a mean difference of 4.21 kg.
In plain wordsIn adolescents with overweight or obesity, GLP-1 drugs as a group lowered weight more than placebo.
Peptide
Liraglutide
Outcome
DecreaseWeight change, pooled GLP-1RAs versus placebo
Study
n = 883
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Measurements
Weight mean difference
−4.21 kg
pooled GLP-1RAs vs placebo
Source sentences
Summary
GLP-1RAs reduced weight (mean difference -4.21 kg, 95% confidence interval [CI] -7.08 to -1.35)
1 context sentence(design, population, supporting numbers)
Summary · context
For this systematic review and network meta-analysis, we searched five databases and registries until 2 March 2024 for eligible randomized controlled trials (RCTs).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3904430601
04HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adolescents with overweight or obesity, pooled GLP-1 receptor agonists (including semaglutide) reduced weight versus placebo by a mean difference of 4.21 kg.
In plain wordsIn adolescents with overweight or obesity, GLP-1 drugs as a group lowered weight more than placebo.
Peptide
Semaglutide
Outcome
DecreaseWeight change, pooled GLP-1RAs versus placebo
Study
n = 883
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Measurements
Weight mean difference
−4.21 kg
pooled GLP-1RAs vs placebo
Source sentences
Summary
GLP-1RAs reduced weight (mean difference -4.21 kg, 95% confidence interval [CI] -7.08 to -1.35)
1 context sentence(design, population, supporting numbers)
Summary · context
For this systematic review and network meta-analysis, we searched five databases and registries until 2 March 2024 for eligible randomized controlled trials (RCTs).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3904430602
05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adolescents with overweight or obesity, pooled GLP-1 receptor agonists (including liraglutide) reduced BMI versus placebo by a mean difference of 2.11 kg/m².
In plain wordsIn adolescents with overweight or obesity, GLP-1 drugs as a group lowered BMI more than placebo.
Peptide
Liraglutide
Outcome
DecreaseBMI change, pooled GLP-1RAs versus placebo
Study
n = 883
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Measurements
BMI mean difference
−2.11 kg/m²
pooled GLP-1RAs vs placebo
Source sentences
Summary
and body mass index (BMI; mean difference -2.11 kg/m², 95% CI -3.60 to -0.62)
1 context sentence(design, population, supporting numbers)
Summary · context
For this systematic review and network meta-analysis, we searched five databases and registries until 2 March 2024 for eligible randomized controlled trials (RCTs).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3904430603
06HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adolescents with overweight or obesity, pooled GLP-1 receptor agonists (including semaglutide) reduced BMI versus placebo by a mean difference of 2.11 kg/m².
In plain wordsIn adolescents with overweight or obesity, GLP-1 drugs as a group lowered BMI more than placebo.
Peptide
Semaglutide
Outcome
DecreaseBMI change, pooled GLP-1RAs versus placebo
Study
n = 883
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Measurements
BMI mean difference
−2.11 kg/m²
pooled GLP-1RAs vs placebo
Source sentences
Summary
and body mass index (BMI; mean difference -2.11 kg/m², 95% CI -3.60 to -0.62)
1 context sentence(design, population, supporting numbers)
Summary · context
For this systematic review and network meta-analysis, we searched five databases and registries until 2 March 2024 for eligible randomized controlled trials (RCTs).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3904430604

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.